Innate Pharma SA
With more than 30 years of financial experience, Pascale Boissel is an expert in finance, audit, transactions, internal control, growth management and restructuring operations. Her experience has been represented in a variety of industries, including: food and beverage (Danone), building materials (Lafarge Holcim), education and, more recently healthcare and biotechnology.
Before, she was Chief Financial Officer of ENYO Pharma. Pascale was the Deputy-Chief Executive Officer and Head of Finance and Administration of the BIOASTER Institute (IRT), a French not-for-profit organization that develops collaborative research programs in the field of infectious diseases and microbiology. In 2009, Madame Boissel joined Ipsogen a listed biotech company in the diagnostics field as CFO. Pascale Boissel began her career in audit and corporate finance at PricewaterhouseCoopers Paris.
This person is not in the org chart
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.